News and Events

Comprehensive overview of the current knowledge regarding conjunctival melanoma

14 June 2021

This review aims to provide a comprehensive overview of the current knowledge regarding conjunctival melanoma (CoM), with a focus on the genetic and immunologic understanding. The authors elaborate on the distinct position of CoM in contrast to other types of melanoma, and explain how new insights in the pathophysiology of this disease guide the development of new, personalized, treatments.

62,130 children estimated to be using sunbeds in England

11 June 2021

According to this recent study, estimated mean prevalence of sunbed use was 0.6% for 11- to 14-year-olds and 2.5% for 15- to 17-year-olds, equating to 62,130 children using sunbeds in England. A predicted 2958 premises and 17,865 sunbeds exist nationally and a ‘buy-back’ scheme would cost approximately GBP 21.7 million. 

Ipilimumab plus anti-PD-1 more beneficial than ipilimumab alone as second-line immunotherapy for advanced melanoma patients resistant to anti-PD-(L)1

9 June 2021

According to this recent study, in patients who are resistant to anti-PD-(L)1, ipilimumab plus anti-PD-1 seemed to yield higher efficacy than ipilimumab with a higher objective response rate, longer progression-free, and longer overall survival, with a similar rate of grade 3–5 toxicity. The study concludes that ipilimumab plus anti-PD-1 should be favoured over ipilimumab alone as a second-line immunotherapy for these patients with advanced melanoma.

Benefit of local therapy for patients with melanoma treated for solitary progression after initial response to immune checkpoint inhibition

9 June 2021

This recent study evaluates the role of local therapy for solitary progression in melanoma. It concludes that almost half of patients with melanoma treated for solitary progression after initial response to immune checkpoint inhibition had no subsequent progression. The study suggests that local therapy can benefit patients and is associated with favourable long-term outcomes.

Hypoxia-dependent drivers of melanoma progression

9 June 2021

According to this recent review, the increasing knowledge of hypoxia-regulated pathways in melanoma progression and the promising results obtained from novel antiangiogenic therapies could offer new perspectives in clinical practice in order to improve survival outcomes of melanoma patients.

Long-lasting response in patients with metastatic melanoma after anti-PD-1 cessation

27 May 2021

This recent study aimed to evaluate the progression-free survival (PFS) of patients with metastatic melanoma after anti-PD-1 interruption for objective response (OR) or limiting toxicity during clinical trials. The cohort of the study shows a global recurrence rate of 18.5% and confirms a long-lasting response after anti-PD-1 cessation regardless of the cause of discontinuation.